The Medudy course on ARLDDs and the rechARge study, presented by Professor Axel Merseburger, Director of the Department of Urology at the University of Lübeck, provides practical knowledge on a novel therapeutic approach to metastatic castration-resistant prostate cancer (mCRPC).
This unit introduces the novel mechanism of action of the androgen receptor ligand-directed degrader (ARLDD). Particular attention is paid to the first-in-class ARLDD '365, which acts both as a competitive inhibitor and as a degrader of the androgen receptor, thereby addressing classic resistance mechanisms to established androgen receptor signaling pathway inhibitors.
In addition, the global Phase III rechARge study, which is currently recruiting, will be presented. Participants will receive an overview of the scientific rationale, preclinical and clinical Phase 1 data, and the adaptive study design of the rechARge study, including inclusion and exclusion criteria, endpoints, and recruitment status.
Note: All "speakers" appearing in Medudy videos are AI-based avatars. The individuals depicted have explicitly consented to their use. All content is based on current scientific data and has been created and reviewed by the Medudy medical team.
At the end of this training you will know:
- The limitations of current androgen receptor signaling pathway inhibitors in mCRPC
- the mechanism of action of androgen receptor ligand-directed degraders (ARLDD)
- the Phase 1 clinical data on the efficacy and safety of ARLDD '365
- Structure, design, and objectives of the Phase III rechARge study
- Relevant inclusion and exclusion criteria for study participation
